United States, March 20 -- The U.S. Food and Drug Administration approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, called Wegovy HD, for weight loss and long-term maintenance of weight loss for certain adult patients. The decision was granted just 54 days after filing and represented the fourth approval under the Commissioner's National Priority Voucher (CNPV) pilot program. Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist. The new higher dose of Wegovy is indicated to reduce excess body weight and maintain weight reduction long-term in adults with obesity, or overweight with at least one weight-related condition. The approval of a new higher dose will provide adult patients with an additional therapeutic op...